60 / 160
612
70. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Inhibition
of intestinal cholesterol absorption by ezetimibe is a novel
therapeutic target for fatty liver. Med Hypotheses 2006; 66:
844-6.
71. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term
ezetimibe therapy in patients with nonalcoholic fatty liver disease.
J Gastroenterol 2011; 46: 101-7.
72. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an
angiotensin II receptor antagonist in patients with nonalcoholic
steatohepatitis. Hepatology 2004; 40: 1222-5.
73. Paschos P, Tziomalos K: Nonalcoholic fatty liver disease and the
renin-angiotensin system: implicationsfor treatment. W J Hepatol
2012: 4: 327-331.
74. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C.
Mortality in randomized trials of antioxidant supplements for
primary and secondary prevention: systematicreview and meta-
analysis. JAMA 2007; 297: 842-57.
75. Romanelli RG, Caligiuri A, Carloni V, et al: Effect of pentoxifyline on
the degradation of procolagen typi I produced by human hepatic
stellate cells in response to transforming growth factor-B1. Br J
Pharmacol 1997;122:1047-54.
76. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK.
Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis
and necroinflammation in patients with non-alcoholic
steatohepatitis. J Gastroenterol Hepatol 2007; 22: 634-8.
77. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves
nonalcoholic steatohepatitis: a randomized placebo-controlled
trial. Hepatology 2011. Nov; 54(5):1610-9.
78 . Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic
fatty liver disease and/or steatohepatitis. Cochrane Database Syst
Rev 2007; (1): CD005160.
79. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK,
Dierkhising RA: Frequency and outcomes of liver transplantation
for nonoalcoholic steatohepatitis in the Unites States.
Gastroenterology 2011; 141: 1249-53.
80. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J:
Recurrent disease following liver transplantation for nonalcoholic
steatohepatitis cirrhosis. Liver Transplant 2009; 15: 1843-51.
[REV. MED. CLIN. CONDES - 2015; 26(5) 600-612]